Vacis, a Geleen, the Netherlands-based company commercializing a medical device that enables a patient’s body to create blood vessels using the patient’s own cells, has closed a further funding round of undisclosed amount.
Backers included Brightlands Venture Partners and LIOF through their Limburg Business Development Fund (LBDF), as well as the German High-Tech Gründerfonds (HTGF). This was supplemented by Innovation Credit from RVO (the Netherlands Enterprise Agency).
The company intends to use the funds to set up GMP production, execute clinical trials and obtain CE certification.
Led by Ken Messier, Vacis is a biotech company focused on tissue engineering and on commercializing a medical device that enables a patient’s body to create blood vessels using the patient’s own cells. It is currently evaluating its first application, hemodialysis access for kidney failure patients, of its product in clinical trials.
The medical device is a synthetic rod with a specialized surface that is inserted under the skin. This induces the body to form a tissue capsule, which in the right environment, further matures into a functional blood vessel that is used as a vascular access site for hemodialysis.
The team has been expanded with two seasoned biotech managers, Ken Messier and Josephine Brackman. They both join Dominik Klump, the Chief Technology Officer of Vacis, in the management team at the location in Geleen.